Tysabri Progressive Multifocal Leukoencephalopathy Settlement: California Injury Lawyer

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Education to Targeted Risk Awareness

For decades, general health and science communication has served as the foundation for public understanding of medical risks and therapeutic benefits. This legacy context established frameworks for evaluating how biological treatments interact with patient populations, emphasizing the importance of informed decision-making in clinical settings. Within this broad informational landscape, the focus has gradually shifted toward specific pharmaceutical interventions and their real-world implications for patient safety. As the discourse matured, attention turned to disease-modifying therapies used in chronic conditions, particularly those requiring sustained immunosuppression. Among these, Tysabri (natalizumab) emerged as a significant treatment option, yet its association with progressive multifocal leukoencephalopathy (PML) introduced a critical risk consideration. This transition from general health education to targeted risk awareness reflects a natural progression in medical communication, where population-level safety data becomes increasingly relevant to individual treatment decisions. The occupational exposure dimension now enters this framework through the lens of legal and clinical accountability. When patients or their families seek recourse following adverse outcomes, the question of exposure—whether through prescribed therapy or environmental factors—becomes paramount. This pivot from general health information to specific exposure concerns underscores the need for precise risk assessment in both medical and legal contexts, particularly when evaluating the circumstances surrounding PML development in Tysabri-treated individuals.

Find Out If You Qualify for Compensation →

Understanding Tysabri and Its PML Risk

Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus. The United States Food and Drug Administration (FDA) has issued a boxed warning for Tysabri, stating that the drug "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning is based on clinical evidence and postmarketing surveillance. PML is caused by the reactivation of the JC virus in immunocompromised individuals. Tysabri works by blocking the migration of immune cells into the central nervous system, which can impair the body's ability to control JC virus replication. The FDA label identifies three primary risk factors for PML in Tysabri-treated patients: "the presence of anti-JCV antibodies, duration of therapy, and prior use of immunosuppressants" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who test positive for anti-JCV antibodies have a higher risk of developing PML. Longer treatment duration, especially beyond two years, further increases this risk. Prior use of immunosuppressive medications also elevates the likelihood of PML.

Clinical Presentation and Diagnosis of PML

The clinical presentation of PML can vary, but common symptoms include progressive neurological deficits such as weakness, cognitive impairment, and coordination problems. The FDA label advises healthcare professionals to "monitor patients on TYSABRI for any new sign or symptom that may be suggestive of PML" and to "withhold TYSABRI immediately at the first sign or symptom suggestive of PML" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Diagnosis typically involves magnetic resonance imaging of the brain and detection of JC virus DNA in cerebrospinal fluid. Early recognition is critical, as PML often leads to severe disability or death. The FDA Adverse Event Reporting System (FAERS) database contains numerous reports associated with Tysabri, including fatigue, multiple sclerosis relapse, headache, and gait disturbance (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not directly confirm PML, they highlight the range of adverse events experienced by patients. PML itself is a rare but devastating complication, and its occurrence has led to significant legal and regulatory actions.

Regulatory Warnings and the TOUCH Program

The adequacy of warnings regarding Tysabri and PML has been a subject of scrutiny. The FDA requires a boxed warning, and Tysabri is only available through a restricted distribution program called the TOUCH Prescribing Program. This program mandates that "patients must be enrolled in the TOUCH Prescribing Program, read the Medication Guide, understand the risks associated with TYSABRI, and complete and sign the Patient Enrollment Form" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, some patients and their families have argued that the risks were not adequately communicated, leading to settlements and legal claims. For patients affected by PML, settlement-related considerations often involve the timeline between exposure and documented harm. PML can develop months to years after starting Tysabri, and the FDA label notes that "the duration of treatment with TYSABRI prior to onset ranged from a few months to several years" for other serious infections like herpes encephalitis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This variability complicates the attribution of harm to the drug.

Legal Recourse for California Patients

Legal claims may focus on whether the manufacturer provided sufficient warnings and whether the patient's specific risk factors were properly assessed. In California, patients who have developed PML after using Tysabri may seek legal recourse through injury lawyers specializing in pharmaceutical litigation. These cases often involve complex medical evidence, including documentation of anti-JCV antibody status, treatment duration, and prior immunosuppressant use. The FDA label explicitly states that "three factors that are known to increase the risk of PML in TYSABRI-treated patients have been identified: The presence of anti-JCV antibodies... Longer treatment duration, especially beyond 2 years" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This information is critical for establishing a causal link between Tysabri and PML. The mechanistic pathway linking Tysabri to PML involves the drug's effect on immune surveillance. By inhibiting the adhesion of lymphocytes to endothelial cells, Tysabri reduces the entry of immune cells into the brain. This creates an environment where JC virus can replicate unchecked, leading to PML. The FDA label describes PML as "an opportunistic viral infection of the brain caused by the JC virus (JCV) that typically only occurs in patients who are immunocompromised" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Tysabri-induced immunosuppression is the key mechanism.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Tysabri and how does it cause PML?

Tysabri (natalizumab) is a biologic therapy for multiple sclerosis and Crohn's disease. It increases the risk of progressive multifocal leukoencephalopathy (PML) by blocking immune cell migration into the brain, allowing JC virus replication. The FDA label identifies anti-JCV antibodies, longer treatment duration, and prior immunosuppressant use as key risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the symptoms and diagnosis of PML?

PML symptoms include progressive neurological deficits like weakness, cognitive impairment, and coordination problems. Diagnosis involves MRI and detection of JC virus DNA in cerebrospinal fluid. The FDA advises withholding Tysabri at the first sign suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Can California patients file a lawsuit for Tysabri-related PML?

Yes, California patients who developed PML after Tysabri use may seek legal recourse through injury lawyers. Claims often involve inadequate warnings and failure to assess risk factors like anti-JCV antibody status and treatment duration. The FDA label provides critical evidence for establishing a causal link (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Find Out If You Qualify for Compensation

Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.